Search

BPH

Globally, benign prostatic hyperplasia (BPH), or enlarged prostate, is a common condition in older men. While not life-threatening, it can cause significant symptoms and affect overall well-being considerably. At the same time, prostate cancer stands as the second most commonly diagnosed cancer in men worldwide, with more than 1.4 million new cases annually. 1

At Canon, we support clinicians with advanced imaging technologies and integrated workflows designed to provide a confident diagnosis and enhance patient comfort and safety across the entire care pathway.

Benign Prostate Hyperplasia

Over 50% of men over the age of 50 experience symptoms related to Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate. 2,3

Learn more
BPH

Prostate Cancer

Prostate cancer is the most commonly diagnosed cancer among men worldwide, with more than 1.4 million new cases annually.

Learn more
BPH

Our solutions

Ultrasound

  • Fast and accurate biopsy with 3D biopsy core mapping of the prostate
  • High image quality and automated prostate segmentation for precise navigation
Learn more

Magnetic Resonance

  • Automatic positioning with Prostate Line⁺
  • High quality imaging in short scan time with Advanced intelligent Clear-IQ Engine (AiCE) and Precise IQ Engine (PIQE) 
  • Distortion correction and enhanced resolution in challenging patients with RDC DWI

Computed Tomography

  • Clear visualization of adjacent soft tissue structures free from artifact with Single Energy Metal Artifact Reduction (SEMAR)
  • Superior image quality with AiCE

Healthcare IT

  • Instant comprehensive lesion assessment and high-quality diffusion assessment
  • Report including lesion location and volumes
  • PI-RADS V2 recommendations to standardize terminology and content of reports and clarify the level of suspicion or risk of clinically significant tumors
Learn more

Molecular Imaging

  • 27 cm detector for optimized performance in prostate cancer imaging
  • Accurate assessment of metastasis or recurrence in prostate cancer with PSMA-target PET tracers

Angiography

  • Combined fluoroscopy and advanced CT imaging in a single Alphenix 4D CT suite for comprehensive anatomical visualization
  • Accurate identification of prostatic arteries with high-resolution 3D imaging
Learn more

References

  1. Culp, M.B., et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol, 2020. 77: 38. https://www.ncbi.nlm.nih.gov/pubmed/31493960
  2. Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med 2016; 67:137–151.
  3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132(3): 474–479.